Champions Oncology (United States)

Recent papers from Champions Oncology (United States)

1. Investigating new opportunities to combat stigma in healthcare through a “universal” approach: findings from a longitudinal study of healthcare workers in Mombasa, KenyaFrontiers in Public Health · 2026
2. The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric CancersCancer Research · 2026
3. Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for HepatoblastomaInternational Journal of Molecular Sciences · 2026
4. Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in HepatoblastomaCells · 2026
5. Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibitionActa Pharmacologica Sinica · 2026
6. Abstract LB435: Large-scale foundation model-based PDX model selection and cancer subtype assignmentCancer Research · 2026
7. Identification and credentialing of invasive lobular carcinoma patient-derived Xenograft modelsDisease Models & Mechanisms · 2026
8. Abstract 4868: Modelling glioblastoma sensitivity to irradiation with a patient derived xenograft-derived 3D platformCancer Research · 2026
9. Abstract 6415: Champions: Scalable chem-seq and functional-seq platforms for profiling chemical and genetic perturbations in patient-derived organoidsCancer Research · 2026
10. Abstract 4543: A novel CDH17-targeted radioligand therapy overcomes resistance to microtubule and topoisomerase I inhibitor ADCs and achieves potent efficacy in GI-tract tumorsCancer Research · 2026
11. Abstract 5812: Preclinical evaluation of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in mice bearing castration-resistant prostate adenocarcinoma patient-derived xenograftsCancer Research · 2026
12. Abstract 2461: Aging reprograms early oncogenic responses to Braf V600E activation in colon organoids through altered growth phenotype, senescence, and secretory signalingCancer Research · 2026
13. Abstract 2832: Evaluation of Natural Killer cells’ contribution to Enhertu toxicity in breast cancer patient derived xenograft-derived 3D modelsCancer Research · 2026
14. Abstract 7147: CAR T-Cell therapy efficacy evaluation inTumorGraft3D tri-culture platform with reconstructed tumor microenvironmentCancer Research · 2026
15. Abstract 1884: Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models.Cancer Research · 2026
16. Abstract 525: Assessment of the RAD51 assay as homologous recombination deficiency surrogate in a large cohort of hormone-dependent cancer PDXs.Cancer Research · 2026
17. Abstract 7162: CD180-targeting ADCs with a topoisomerase I inhibitor payload achieve strong efficacy in AML tumorsCancer Research · 2026
18. Abstract 7213: Evaluation of folate receptor-alpha antibody-drug conjugate mirvetuximab soravtansine-gynx in ovarian cancer PDXsCancer Research · 2026
19. Abstract 6807: Mitochondrial genome alterations as early drivers of lung adenocarcinoma evolutionCancer Research · 2026
20. Abstract 7214: LymphGen-based stratification of DLBCL PDX models mirrors clinical tumor complexityCancer Research · 2026